Company ProfilePremium

Daihan Pharmaceutical Co., Ltd.

Company Profile Analysis

Ticker: 023910.KQ대한약품공업주식회사

ESOMAR 23 Corporate BadgeISO Certifications Badge
Daihan Pharmaceutical Co., Ltd. - Company showcase

Year Founded & Workforce

1945

768 Employees

Daihan Pharmaceutical Co., Ltd. logo

Daihan Pharmaceutical Co., Ltd. Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Daihan Pharmaceutical Co., Ltd. Overview

Daihan Pharmaceutical is Korea's pioneer manufacturer of intravenous (IV) infusion solutions. The company dates its first IV production to 1953 [S1]. It remains one of three firms that control the domestic basic-IV oligopoly, alongside the JW group (JW Pharmaceutical / JW Life Science) and HK inno.N [S1][S6].

All output comes from one highly automated plant in Ansan. More than 80% of sales go to general and tertiary hospitals [S2-summary][S35].

The economics are unusual for a Korean generic-drug company. Most core basic IVs are designated "exit-prevention drugs" (퇴장방지의약품). This shields them from post-listing price cuts and allows cost-based price-ceiling adjustments [S1]. Scale and automation then delivered operating margins of about 18% for a decade [S8].

The company has no debt and held net cash of KRW 121.4 bn at mid-2026, equal to about 76% of market capitalisation [S1].

Three issues dominate the investment debate:

Concentration: About 68% of revenue comes from IV solutions and almost all sales are domestic.

Thin R&D: R&D spending is about 1% of revenue.

Succession and capital allocation: These questions have kept the stock at about 0.5x book value.


Company's own description

The company says it was founded in 1945 and makes and sells more than 200 pharmaceutical products [S11]. The range covers basic IV solutions, special IV solutions, injectables, OTC drugs, dialysis solutions and quasi-drugs.

It groups activity into four areas [S11]:

Pharmaceutical manufacturing and sale: Prescription drugs are made on sterile parenteral lines that span small-volume ampoules and vials through large-volume infusions and dialysates, plus inhalants and oral forms. OTC sterile liquids include irrigation saline, irrigation water and sodium chloride solution. Quasi-drugs include the "Eye-con" (아이콘액) contact-lens solution.

Exports: of infusions and injectables.

Technology export: This takes the form of plant-related know-how transfer and business partnering.

R&D and quality assurance: The company also states an ambition to extend into manufacturing equipment, medical devices and health-functional products [S11]. No material revenue from these lines was identified.

Independent characterisation

Daihan is a single-site, high-volume sterile-liquids manufacturer. Its economics resemble a regulated utility more than a research-based drug company.

Revenue model. Revenue is almost entirely product sales. Daihan has no subscription or royalty income of note, and its plant-technology transfer income is immaterial and not separately disclosed.

Demand drivers. Core demand is tied to inpatient bed-days. Basic IVs (glucose, saline, electrolyte solutions such as Hartmann's and Darrow's) are consumed per hospital admission. Analysts therefore model volume growth from population ageing and hospital admission days rather than from new-product cycles [S13][S29].

Pricing. Pricing is largely set by the National Health Insurance listing system. Exit-prevention status protects price but caps upside. Price increases require a cost-based application [S1][S13].

Channels. More than 80% of revenue is supplied to hospitals and clinics through the company's own sales network [S35][S2-summary]. Pharmacies are reached for OTC sterile-liquid and lens-care products.

Value-chain position. The company is a vertically integrated formulator and filler. Historically it also made its own containers (it set up an IV glass-bottle works in 1953) [S11]. It has in-house capability for about 20 active pharmaceutical ingredients, built after the central research institute opened in 1987/88 [S31].

Key purchased inputs. These are bulk chemicals (glucose, salts, amino acids) and polymer packaging (non-PVC bags, PP bottles, ports and caps). Packaging and components are estimated at 30–40% of IV production cost [S7].

End-markets and customers:

  • Hospital inpatient care (general and tertiary hospitals): fluid replacement and electrolyte balance.

  • Parenteral nutrition: amino acid solutions and a small three-chamber TPN position.

  • Anaesthesia and surgery: local anaesthetics in ampoules, irrigation solutions.

  • Renal care: dialysis solutions.

  • Retail pharmacy: sterile saline and lens-care.

Strategy

Stated strategy. Daihan does not publish a formal medium-term plan or investor-day material. Its strategy can be read from filings, press and actions [S8][S9][S35]:

  1. Stay concentrated on IVs and injectables, reinvesting profits in production infrastructure (automation, warehousing) rather than diversifying. Management treats facilities and process as the competitive moat in an equipment-intensive industry [S8].

  2. Ageing-linked volume growth: basic-IV demand tracks inpatient days and the elderly population [S13][S35].

  3. Cost discipline: keeping cost of sales at about 66% and SG&A at about 15% of revenue historically [S35]; both ratios worsened in FY2025.

  4. Capacity expansion: a new plant is planned on 3,000 pyeong of the expansion site, described as supporting growth "including global business" [S9]. Timing, budget and products are not disclosed.

  5. Higher-value nutrition: the three-chamber TPN entry (Tetraprof), launched after 2021 approval, with a non-reimbursed-first, reimbursement-later strategy [S28][S20]. KIR identifies nutritional-IV growth as a re-rating lever [S1].

  6. Shareholder returns: DPS raised four years in a row (KRW 400 → 1,000), a KRW 3 bn buyback in 2022, and owner open-market purchases [S12][S15][S30-2].

Initiatives in the last 24 months:

  • Automated-warehouse completion (May 2024) and line upgrades; FY2025 capex of KRW 25.1 bn [S4].

  • Designation as a Supply-Stability Leading Company (1 Aug 2026 – 31 Jul 2027). This gives a 50% (instead of 45%) price-calculation rate on new generic listings for up to 1+3 years if domestically produced [S10][S-dailypharm 341047].

  • Supply management through the naphtha shock, supported by government priority allocation of naphtha to IV bags [S6][S7].

ESG or cost programmes with targets: none disclosed.

Medium-term financial targets or guidance: not publicly disclosed. The company does not issue guidance. The KIR FY2026 estimate (revenue KRW 220.0 bn; OP KRW 29.5 bn; NI KRW 25.0 bn) is a third-party forecast [S1].

Products & Services

The company website lists 99 products in its searchable catalogue across prescription, OTC and quasi-drug categories [S11-products]. It describes the overall range as about 200 finished products [S11]. Product-level revenue and pricing are not publicly disclosed.

The table below lists named products identified in public sources. It is not exhaustive.

Basic and electrolyte IV solutions (core; exit-prevention-drug heavy)

ProductDescriptionTarget / useNotes
Daihan 10% Dextrose in Saline (대한10%포도당가생리식염액)Dextrose-saline maintenance fluidHospital inpatientsCatalogue item [S11-products]
Daihan 20% Dextrose Injection (대한20%포도당주사액)Concentrated glucoseCaloric supplementationCatalogue item [S11-products]
Daihan Plascon Inj. (대한플라스콘주)Multi-electrolyte solution suited to extracellular fluid (ECF) replacementPeri-operative, ICUFeatured product [S11]
Hartmann's and Darrow's solutionsElectrolyte IVsFluid and electrolyte replacementHistoric core range since 1977 [S11][S1]
Inveton (인베톤)Invert-sugar IVEnergy supplyDeveloped 1959 [S11]
Multiplex Peri (멀티플렉스페리) 550/1,100 mLPeripheral IV in multi-port bagPeripheral nutrition/fluidsProduct gallery [S11-gallery]
FormatsNon-PVC bags (500/1,000 mL), PP bottles, Flumat-port bags, PE Bottle-Pack—[S11-gallery]

Nutritional IV solutions

ProductDescriptionTargetLaunch / status
Armix Inj. (아르믹스주)Complete amino-acid solution optimised for TPN compoundingHospital pharmacies, ICUFeatured product [S11]
Nutrihex Inj. (뉴트리헥스주)Nutritional infusionHospitalCatalogue [S11-products]
Nephrisol Inj. (네프리솔주)Renal-type amino-acid infusion (by name)Renal patientsCatalogue [S11-products]
Glypurol Inj. (글리푸롤주)Glycerol-based infusion (by name)HospitalCatalogue [S11-products]
Tetraprof Inj. / Tetraprof Peri Inj. (테트라프주/테트라프페리주)Three-chamber lipid/amino-acid/glucose TPN; generic of SMOFKabiven / PeripheralCentral and peripheral parenteral nutritionMFDS approval Sep 2021. Launch was delayed because reimbursement listing was not obtained [S20][S28]. A non-reimbursed launch was reported for the year before Dailypharm's 2022 article [S34]; commercial scale not disclosed. A higher omega-3 version was reportedly planned [S-dailypharm 2023-12].

Ampoules and vials (small-volume parenterals)

ProductDescriptionNotes
Lidocaine HCl hydrate Inj. 20 mL (리도카인염산염수화물주)Local anaesthetic, PP ampouleExport version for Hong Kong noted in the product gallery [S11-gallery]
Bonorex 300/350 Inj. (보노렉스)Contrast-medium-type injection (by naming)Product gallery [S11-gallery]
Anaesthetic and contrast media rangesGrouped in the product gallery[S11-gallery]
20 mL PP ampoulesPlastic ampoule format[S11-gallery]

Other prescription products

CategoryExamples / notes
Oral solidsGamofree Tab. (가모프리정, mosapride citrate) [S11-products]
Dialysis solutionsHaemodialysis/peritoneal dialysates (product gallery "투석액") [S11-gallery]
APIsIn-house APIs (about 20 technologies) [S31]
Inhalants, antibiotics, hormones, antidotes, sedatives, analgesicsListed by an aggregator profile [S-roic]; not individually verified

OTC and quasi-drugs (pharmacy channel)

ProductDescription
Daihan Sterile Saline for Irrigation (대한관류용멸균생리식염)Sterile irrigation saline (OTC) [S11]
Daihan Sterile Water for Irrigation (대한관류용멸균증류수)Sterile irrigation water [S11]
Daihan Sodium Chloride Solution (대한염화나트륨액)Sterile NaCl solution [S11]
Daihan Sterile Saline 10 mL (대한멸균생리식염수)Featured product [S11]
Eye-con (아이콘액)Contact-lens cleaning solution (quasi-drug) [S11]

Pricing model. Prescription products are sold at or below National Health Insurance (NHI) ceiling prices. Exit-prevention products are excluded from actual-transaction price cuts [S-MOHW 2025] and can apply for cost-preservation ceiling increases [S1]. OTC and quasi-drug pricing is not disclosed.

Financial Narrative

Income statement

Sources: annual figures from Butler/DART [S5], confirmed by the FY2025 earnings disclosure [S27] and KIR [S1]. EPS is derived as NI ÷ 6.0 M issued shares, the basis used by ValueLine [S2]. DART EPS uses weighted shares excluding treasury stock and will be about 2% higher. DPS is from LS Securities [S12] and dividend records [S15].

Revenue CAGR FY2021–FY2025: about 5.0% a year. Since the 1994 listing, KIR calculates average revenue growth of 8.8% a year with no operating loss in 32 years [S1].

Diluted EPS: No convertible or warrant instruments were identified, so diluted EPS equals basic EPS.

FY2025 detailed P&L. ValueLine's FY2025 column and its TTM to March 2025, used as an FY2024 proxy, give the following [S2]:

Quarterly trajectory (derived). Quarterly figures for 2024 come from LS Securities [S12]. Quarters for 2025 and 2026 are back-calculated from ValueLine TTM series [S2] and reconcile to the reported 9M2025 OP of KRW 27.6 bn [S8] and FY2025 totals.

H1 2026 (derived): revenue of about KRW 109.3 bn (+7.8% YoY) and operating income of about KRW 15.9 bn (-6% YoY), for an operating margin of about 14.6%. The half-year report was filed on 14 Aug 2026 [S5].

Commentary — growth. FY2021–FY2024 was a clean volume-led recovery from the COVID-19 trough, with 12 straight quarters of YoY revenue growth to Q1 2024 [S13]. Brokers attribute the growth almost entirely to quantity (Q). Exit-prevention status prevented price cuts, but health-insurance budget constraints also prevented price rises [S13][S21-1Q23].

In FY2025, IV revenue declined 9% [S6]. Total revenue still edged up 2.2%, helped by the "other" category (see §4.2 on comparability).

Commentary — the FY2025 margin inflection. Operating margin fell 3.7 pp to 15.0%, the lowest level in at least five years. Four drivers stand out:

  1. Labour inflation: cost-of-sales labour was up about KRW 3.8 bn versus the FY2024 proxy.

  2. Depreciation step-up: about +KRW 1.8 bn in cost of sales. In FY2025, construction-in-progress of KRW 18.2 bn moved into structures and machinery, reflecting the automated-warehouse and line investments [S3].

  3. Raw-material cost creep.

  4. Negative operating leverage on lower IV volumes during the medical crisis [S6].

Q4 2025 was exceptionally weak, with an operating margin of about 7%. The sources do not disclose the specific cause. Possible explanations include year-end bonuses, retirement-benefit charges, inventory adjustments, or one-off costs.

Commentary — 2026. H1 2026 revenue recovered as hospital volumes normalised after the medical crisis officially ended in October 2025 [S6]. Margins, however, stayed compressed at about 14–15%. The Middle East conflict pushed naphtha prices up by about 50%, raising IV-bag and component costs; packaging is 30–40% of IV cost [S7]. KIR forecasts FY2026 OP of KRW 29.5 bn (operating margin 13.4%) on revenue of KRW 220.0 bn [S1].

Balance sheet

Source: ValueLine (DART stand-alone) [S3].

Net cash. KIR puts net cash at KRW 121.4 bn at end-June 2026: cash equivalents of KRW 59.6 bn plus deposit-type financial assets of KRW 61.8 bn, equal to about 76% of market capitalisation [S1].

At FY2025, other current assets of about KRW 42.5 bn appear to be short-term deposits classified outside "short-term financial instruments." Including these, cash-like assets were about KRW 90 bn at Q3/Q4 2025. This matches press reports of cash near KRW 90 bn [S8].

The apparent fall in "cash" from FY2023 to FY2025 therefore mainly reflects reclassification into term deposits and investment assets, plus capex, rather than cash burn.

Debt. Borrowings fell to zero during 2023. Dailypharm reported the decline as KRW 16.7 bn to zero [S20-rel]. Year-end FY2022 borrowings per ValueLine were KRW 6.5 bn [S3], so the 16.7 bn peak was at an intra-year point. The balance sheet has been debt-free since FY2023.

Retained earnings of KRW 308.3 bn (1H2026) make up essentially all of equity. Share capital is KRW 3.0 bn [S3].

Cash flow

Source: ValueLine [S4].

Commentary. FY2025 FCF was almost nil for two reasons:

  1. Capex peaked with completion of the automated-warehouse and line investments.

  2. Working capital absorbed KRW 13.4 bn. Inventory rose KRW 8.1 bn, consistent with weaker IV sell-through during the medical crisis and possibly pre-buying of packaging.

TTM cash conversion has since recovered: OCF of KRW 37.3 bn and FCF of about KRW 20 bn. Historically, annual OCF has run at "KRW 30-odd bn" [S35].

The company has about 5,000 pyeong of land. Of this, 2,000 pyeong is already built out as an automated warehouse, and a new plant is planned on the remaining 3,000 pyeong [S8][S9]. This implies a further capex wave, whose timing and budget are not publicly disclosed.

Ratios

Commentary. Returns are healthy on operating capital: ROIC is about 15% even after the FY2025 margin dip. Reported ROE and ROA, however, are diluted by surplus cash of roughly 40% of equity. This underpins the market's P/B discount and the push from KIR and Dailypharm for buybacks and cancellation, a higher payout, or growth investment [S1][S9].

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Revenue by Segment and Revenue by Segment (%)

MetricFY2023FY2024FY2025

IV solutions revenue (KRW Bn)

151.2156.5142.7

Total revenue (KRW Bn)

195.9204.2208.6

Non-IV revenue, derived (KRW Bn)

44.747.765.9

IV share of revenue (%)

77.276.668.4

IV revenue YoY growth (%)

—3.5-8.8

Basic IV % by Period

PeriodBasic IV %Nutritional IV %Ampoule & vial %Other products %Source

FY2024 (broker figure)

—13.4——

LS Securities [S12]

FY2025

56126

26–27

Employer registry citing filings [S14]

Q2 2026

76168

not shown

Butler [S5]

Income Statement and Margin Analysis (%)

MetricFY2021FY2022FY2023FY2024FY2025

Revenue (KRW Bn)

171.5184.3195.9204.2208.6

Operating income (KRW Bn)

29.133.035.838.131.2

Net income (KRW Bn)

22.725.028.433.827.6

Revenue growth YoY (%)

1.57.56.34.22.2

Operating margin (%)

17.017.918.318.715.0

Net margin (%)

13.213.614.516.613.2

EPS, derived (KRW)

3,7834,1674,7335,6334,607

DPS (KRW)

4006507509001,000

Payout ratio, derived (%)

10.615.615.816.021.7

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Income Statement and Margin Analysis (%) (TTM to Mar-2025 (FY2024 proxy)–TTM to Jun-2026)

Line item (KRW Bn)TTM to Mar-2025 (FY2024 proxy)FY2025TTM to Jun-2026

Revenue

205.1208.6216.6

Cost of sales

135.6143.8152.4

– of which raw materials

70.973.476.0

– of which labour

37.841.642.8

– of which depreciation

6.98.711.1

Gross profit

69.264.864.1

Gross margin (%)

33.731.129.6

SG&A

32.633.634.0

– freight

8.08.18.3

– R&D expense

2.22.21.7

Operating income

37.231.230.1

EBITDA

45.140.542.6

Pre-tax income

39.233.232.9

Income tax

7.95.55.4

Net income

31.327.627.5

Financial Analysis

MetricQ1-24Q2-24Q3-24Q4-24Q1-25Q2-25Q3-25Q4-25Q1-26Q2-26

Revenue (KRW Bn)

49.048.954.851.449.951.556.151.152.756.6

Operating income (KRW Bn)

10.18.410.88.79.27.710.63.67.98.1

Operating margin (%)

20.617.219.716.918.415.018.97.015.014.3

Balance Sheet and Per-Share Data

MetricFY2022FY2023FY2024FY20251H2026

Total assets (KRW Bn)

277.0294.3324.4347.7359.3

Cash & equivalents (KRW Bn)

90.9101.561.344.059.6

Short-term financial instruments (KRW Bn)

6.82.98.94.055.1

Non-current investment assets (KRW Bn)

7.48.152.235.323.9

Trade receivables (KRW Bn)

31.330.931.231.029.6

Inventories (KRW Bn)

24.923.626.733.936.3

PP&E (KRW Bn)

113.2125.9134.4153.4151.3

Goodwill & intangibles (KRW Bn)

0.40.40.40.40.4

Short-term borrowings (KRW Bn)

2.50.00.00.00.0

Long-term borrowings (KRW Bn)

4.00.00.00.00.0

Total liabilities (KRW Bn)

51.646.348.447.551.2

Shareholders' equity (KRW Bn)

225.4248.0276.0300.2308.1

Current assets (KRW Bn)

155.9159.9137.4158.5183.5

Current liabilities (KRW Bn)

42.741.342.643.546.2

Working capital (KRW Bn)

113.2118.694.8115.0137.3

Book value per share (KRW)

37,56641,32945,99950,03651,345

Cash Flow

Metric (KRW Bn)FY2025TTM to Jun-2026

Operating cash flow

25.637.3

Capex (PP&E acquisition)

25.117.2

Free cash flow (OCF – capex)

0.520.2

Dividends paid

5.25.8

Share buybacks

0.00.0

Change in working capital

-13.4-6.7

Depreciation (cash-flow basis)

9.211.6

CAPEX by Year

YearCapex (KRW Bn)
2018

34.5 (automation peak)

10-year average to 2018

13.9

2020–2022 average

8.6
202321.3
202525.1

Returns & Leverage Ratios (%) and Financial Ratios (x)

RatioFY2023FY2024FY2025Notes

ROE (%)

12.012.99.6

NI ÷ average equity; derived

ROA (%)

10.010.98.2

NI ÷ average assets; derived

ROIC (%)

n.c.

n.c.

~15

NOPAT (OP × (1 – 16.6% tax)) ÷ (equity – about KRW 126 bn cash-like assets); approximate

Current ratio (x)

3.873.223.64

1H2026: 3.97

Debt/equity (x)

0.000.000.00

FY2022: 0.03

Liabilities/equity (%)

18.717.515.8

1H2026: 16.6

Net debt/EBITDA (x)

net cash

net cash

net cash

Net cash about 2.9x TTM EBITDA (1H2026)

Asset turnover (x)

0.690.660.62

Revenue ÷ average assets

Cash conversion cycle (days)

n.c.

n.c.

~95

DSO 54 + DIO 86 – DPO 45; year-end balances; approximate

Revenue by Region and Revenue by Region (%)

MetricFY2021TTM Mar-2025TTM Jun-2025

Domestic revenue (KRW Bn)

—199.6202.3

Export revenue (KRW Bn)

—5.45.4

Domestic share (%)

9897.497.4

Share Price and Market Valuation

MetricFY2022FY2023FY2024FY2025

Year-end share price (KRW)

30,60027,75026,20029,250

Market capitalisation (KRW Bn)

183.6166.5157.2175.5

P/E at year-end, derived (x)

7.35.94.76.4

P/B at year-end, derived (x)

0.810.670.570.58

DPS (KRW)

6507509001,000

Dividend yield at year-end (%)

2.12.73.43.4

Capital Markets

MetricDaihan PharmJW Life Science

Market cap (KRW Bn)

~153

177.3 [S22]

P/E TTM (x)

5.6 [S2]

6.8 [S22]

P/B (x)

0.50 [S2]

0.78 [S22]

Dividend yield (%)

~3.9 [S15]

4.9 [S22]

EV, derived (KRW Bn)

~31 (mkt cap – KRW 121.4 bn net cash)

n.c.

EV/EBITDA TTM, derived (x)

~0.7

n.c.

EV/Sales TTM, derived (x)

~0.14

n.c.

Analyst Conclusions

Guidance and consensus

Management guidance: none published.

Third-party estimate (KIR, 26 Aug 2026): FY2026 revenue KRW 220.0 bn (+5.5%), OP KRW 29.5 bn (-5.4%; OPM 13.4%), NI KRW 25.0 bn (-9.5%) [S1].

Implied H2 2026: H1 OP of about KRW 15.9 bn (derived) implies H2 OP of about KRW 13.6 bn, consistent with continued packaging-cost pressure.

Earlier forecast missed: LS Securities expected FY2025 OP of KRW 39.5 bn; the actual was KRW 31.2 bn [S12][S5].

Bull case

  1. Pricing reset. The policy toolkit has shifted in favour of exit-prevention suppliers: thresholds up 10%, stability bonuses, rapid price increases, and the Supply-Stability Leading Company designation [S25][S10]. HK inno.N's 2.7x increase on 11 items shows the scale possible [S6-rel]. If Daihan wins cost-based increases on high-volume IVs, OPM could return to 17–18%.

  2. Volume normalisation plus ageing. H1 2026 revenue was up about 7.8% after the medical crisis ended [S2][S6]. Basic IVs track bed-days in an ageing society [S13].

  3. Balance-sheet optionality. Net cash of KRW 121.4 bn (76% of market cap) means EV is about 0.7x EBITDA [S1]. A buyback-and-cancel or a payout step-up, both flagged by KIR as re-rating keys, would unlock value cheaply.

Bear case

  1. Structural share loss. IV revenue fell 9% in FY2025 while HK inno.N grew 16%. HK inno.N and JW are winning the high-margin nutrition segment [S6].

  2. Cost squeeze without price linkage. Naphtha is up about 50%, packaging is 30–40% of IV cost, and no temporary price-linkage mechanism has been agreed [S7]. Labour and depreciation are also rising [S2].

  3. Value trap governance. The family controls about 40%. The CEO holds 6.37% while a gift-tax overhang of KRW 20 bn+ exists. There are no IR briefings, R&D is about 1%, and there is no articulated growth plan [S9][S1].

Catalysts and monitorables (next 12 months)

  • Outcome of any temporary IV price-linkage or cost-based ceiling increases for Daihan's exit-prevention items [S7][S25].

Q3 and Q4 2026 operating margins: Is the Q4 2025 trough (about 7%) a one-off?

  • Naphtha and packaging cost trends, and the duration of the Middle East disruption [S6].

Capital allocation: any treasury-share cancellation, buyback, or payout policy statement, especially if treasury-cancellation legislation advances.

New-plant capex: announcement for the 3,000-pyeong reserve site [S9].

Succession steps: gift or inheritance transfers between the chairman and the CEO [S9].

TPN traction: Tetraprof reimbursement status and nutritional-IV share [S20].

  • Renewal of the Supply-Stability Leading Company status (expires 31 Jul 2027) [S10].

Analyst verdict

Daihan Pharmaceutical is a rare asset in Korean pharma: an essential-medicine manufacturer with real barriers to entry, policy-protected pricing, three decades without an operating loss, and a debt-free balance sheet. Net cash covers about three-quarters of market capitalisation [S1].

The market prices it at about 0.5x book and below 1x EV/EBITDA. That is effectively zero value for a franchise that generated KRW 30–38 bn of operating profit a year over FY2022–FY2025 [S5].

The discount is not irrational, however. FY2025 showed that the moat protects price better than share. Daihan lost about a tenth of its IV revenue while HK inno.N gained, and it still lacks a meaningful foothold in nutrition, where sector growth and margins are concentrated [S6].

Cost inflation from labour, depreciation on recent automation capex, and a geopolitically driven packaging shock has pulled margins into the mid-teens [S2][S7]. Management has offered the market little in response: no guidance, no IR, about 1% R&D, and an unannounced timeline for its next plant [S9].

The investment case is therefore about catalysts rather than the franchise. Three things would change the picture:

Price: Korea's new pro-supply pricing regime converting into concrete ceiling increases for Daihan's high-volume items.

Capital allocation: a credible move such as cancelling treasury stock, a structured buyback, or a higher payout from the KRW 121 bn cash pile.

Growth: a clear nutrition and capacity strategy for the reserve site.

Succession clarity would remove a persistent overhang.

Absent these, the stock is likely to remain a high-yield (≈3.9%), low-volatility cash proxy with modest earnings growth, consistent with KIR's FY2026 forecast of lower profit on higher sales [S1].

On balance, the risk/reward is asymmetric to the upside on valuation grounds: downside is cushioned by net cash, dividends and policy protection. Timing, however, depends on management action that the company has historically been slow to take. Verdict: fundamentally undervalued, catalyst-dependent; monitor pricing outcomes and capital-allocation signals.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NameTitleTenureBackgroundAge / birth

Lee Seung-young (이승영)

President & sole Representative Director

CEO since 3 Apr 2023. Registered director since about 2016/2017; VP in 2021. Joined in 2001/2002 as a supervisor at the Ansan plant.

Economics, SUNY Stony Brook. Rotated through production, quality, facilities, planning and investment. Led the overseas-business team from about 2009. [S8][S32][S30][S11]

About 53 (2026) [S8]

Lee Yoon-woo (이윤우)

Chairman; largest shareholder

Joined 1969/1970. 5th CEO from 8 Apr 1992 to 3 Apr 2023.

Sungkyunkwan University (Pharmacy); Korea University Graduate School of Business. Chairman of the Korea Pharmaceutical Traders Association (2009). Introduced the Bottle-Pack plastic IV. [S1][S11][S31][S37]

Born 1944 [S1]

Other registered directors

——

As of 2019: Lee Dong-il (sales), Park Young-dae (production), Lim Bang-ho (quality control), Oh Chang-min (finance), Cho Young-ki (accounting) [S-newsthevoice 2019].

—

Major Shareholders

HolderStake (%)As of

Lee Yoon-woo (Chairman)

24.96 (≈1.50 M shares)

20 Aug 2026

Lee Seung-young (CEO)

6.37

20 Aug 2026

Lee Kwang-woo (founder's 2nd son)

3.752,025

Lee Seung-kyung (nephew)

1.872,025

Lee Seung-wook (nephew)

1.872,025

Largest shareholder + 9 related parties (total)

39.96 (≈2.40 M shares)

20 Aug 2026

Fidelity Management & Research

8.50

Jun 2025 (latest public figure; earlier peak 9.99%)

Mirae Asset Global Investments

4.97 (fell below the 5% reporting threshold)

Dec 2023

Treasury shares

about 2.0

2,026

Foreign ownership (total)

20.12

Aug 2026

Major Shareholders by Date

DateStake (%)

May 2013

20.73

Apr 2023

21.06

Dec 2023

22.55

Jun 2025

24.28

Jan 2026

24.63

5 Jun 2026

24.75 (1,484,791 shares; bought at KRW 25,988–27,085)

20 Aug 2026

24.96

Competitive Landscape

Key Competitors

CompetitorSegment overlapScale / dataPositioning

JW Pharmaceutical (JW중외제약)

Basic, special and nutritional IVs (marketer)

FY2025 consolidated revenue KRW 774.8 bn, OP KRW 93.6 bn [S24]. IV revenue KRW 252.9 bn (2025), of which basic KRW 84.1 bn, special KRW 28.8 bn, nutritional KRW 140.1 bn [S6].

Market leader in IVs; Winuf TPN franchise

JW Life Science (JW생명과학)

IV manufacturing arm of the JW group

FY2025 revenue KRW 257.8 bn, OP KRW 33.2 bn [S22]. Mix: TPN 32%, basic 29%, special 26%, haemodialysis 7% (Q2 2026) [S22]. TPN share 54.6% [S-wikidocs JWLS].

Most direct listed peer

HK inno.N (HK이노엔, formerly CJ Healthcare)

Basic and nutritional IVs; Osong IV plant

FY2025 revenue KRW 1,063.2 bn, OP KRW 110.9 bn [S23]. IV revenue KRW 141.7 bn (+16%), nutritional KRW 51.0 bn [S6].

Fast-growing #3, now level with Daihan in IV revenue

Fresenius Kabi Korea

Three-chamber TPN (SMOFKabiven), IVs

Not publicly disclosed (unlisted subsidiary)

Global originator of Tetraprof's reference product

Baxter Korea

TPN (Olimel N9E / N12E)

—

Global TPN player [S21]

MG / WiseMedi (formerly a Yuhan subsidiary)

Three-chamber TPN (Formstna)

—

Niche TPN [S28][S-dailypharm 2024-01]

Huons; Hana Pharm; Dai Han New Pharm

Small-volume injectables, anaesthetic ampoules

—

Ampoule/vial competition (category overlap; not quantified)

B. Braun Korea; other importers

Large-volume parenterals

—

Hospital tender competition

“—” = not publicly disclosed.

Peer Comparison FY2025

MetricDaihan PharmJW Life ScienceHK inno.NJW Pharmaceutical

Revenue (KRW Bn)

208.6257.81,063.2774.8

Revenue growth (%)

2.215.918.57.7

Operating income (KRW Bn)

31.233.2110.993.6

Operating margin (%)

15.012.910.412.1

IV revenue growth 2025 (%)

-8.8—16.02.4

R&D intensity (%)

~1.0

~2.5 (9M25)

——

Company Snapshot

$146.8M

Revenue

768

Employees

1945

Founded

Seoul, South Korea

Headquarters

SWOT Analysis

Strengths

  • Oligopoly position in an essential product. Daihan is one of three basic-IV makers, and policy protection plus scale deter entry [S1].
  • Exit-prevention pricing protection. Core basic IVs are excluded from post-listing price cuts and eligible for cost-based ceiling increases [S1][S-MOHW].
  • Track record. It has had no operating loss since its 1994 listing (32 years) and revenue CAGR of 8.8% [S1]. Its 10-year cumulative OP exceeds KRW 300 bn at about 18% average OPM [S8].
  • Fortress balance sheet. Zero borrowings since 2023; net cash of KRW 121.4 bn equal to 76% of market capitalisation (1H2026) [S1][S3].
  • Automation-led productivity. Revenue grew from KRW 139.4 bn (2016) to KRW 204.2 bn (2024) with minimal headcount growth [S8][S12]. Multiple automated warehouses were completed between 2014 and 2024 [S2-summary].
  • Policy recognition. Named one of only 18 Supply-Stability Leading Companies in July 2026, out of 94 exit-prevention suppliers [S10][S-dailypharm 341047].

Weaknesses

  • Concentration. IVs were 68.4% of FY2025 revenue; domestic sales were about 97–98% [S1][S2][S34].
  • Minimal R&D: about 1% of revenue and 7 R&D staff [S9][S2].
  • Late and weak TPN entry. Tetraprof was approved in 2021, but launch was delayed by lack of reimbursement [S20]. Nutritional IV was about 12% of revenue in FY2025 [S14].
  • Single manufacturing site in Ansan, with no redundancy [S1].
  • Margin compression. OPM fell from 18.7% (FY2024) to 15.0% (FY2025) and about 14.6% (H1 2026, derived) [S5][S2].
  • Weak investor communication. No IR briefings for years, and thin trading volumes, with frequent days under 10,000 shares [S9][S-dailypharm 38752].

Opportunities

  • Post-crisis volume normalisation. H1 2026 revenue rose about 7.8% YoY (derived) [S2].
  • Policy pricing upgrades: the 10% exit-prevention threshold increase, 3% stable-supply bonus, and rapid price increases for supply-unstable items [S25][S-kpanews].
  • Cost-based price applications. HK inno.N's 2.7x increase on 11 IV items (Nov 2025) shows the route exists [S6-rel].
  • Nutritional IV growth. The TPN market is above KRW 180 bn and growing; HK inno.N grew nutrition 31% in 2025 [S21][S6].
  • Capital allocation. Buyback-and-cancellation or a higher payout from net cash; KIR identifies these as the re-rating keys [S1].
  • Capacity expansion on the 3,000-pyeong reserve site, including export ambitions [S9].

Threats

  • Naphtha and packaging inflation. Prices are up about 50% and the war may be prolonged. No price-linkage mechanism has been agreed [S7].
  • Share loss to HK inno.N, whose IV revenue now matches Daihan's [S6].
  • Labour and depreciation cost inflation. Cost-of-sales labour was up about 10% on the FY2024 proxy [S2].
  • Recurrence of hospital-system disruption, as with the 2024–25 doctors' walkout [S6].
  • Succession and control risk. The CEO holds 6.37%; non-aligned family branches hold 7.5%; an estimated KRW 20 bn+ of gift tax looms [S9].
  • NHI financial pressure limiting price increases [S13][S26].

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
17 Apr 2025FY2024 dividend of KRW 900/share paid (+20% YoY) [S15]Fourth consecutive increase
May 2025Q1 2025 results: revenue about KRW 49.9 bn, OP about KRW 9.2 bn (derived) [S2]Medical-crisis drag on volumes
23 Jun 2025Shares hit a 52-week high of KRW 30,600 [S9]Peak of the 2025 re-rating attempt
25–26 Jun 2025Dailypharm assesses the CEO's first two years: revenue above KRW 200 bn, debt-free, but succession and vision gaps; Fidelity at 8.50% [S9]Governance overhang highlighted
2 Jul 2025LS Securities forecasts FY2025 revenue of KRW 210.6 bn and OP of KRW 39.5 bn [S12]Consensus later missed (actual OP KRW 31.2 bn)
Aug 2025H1 2025: revenue about KRW 101.4 bn, OP about KRW 16.9 bn (derived) [S2]Margin slippage visible
Oct 2025National "medical crisis" (resident-doctor walkout) officially ends [S6]Inpatient volume recovery begins
Nov 20259M2025: revenue KRW 157.6 bn, OP KRW 27.6 bn [S8]Stable through Q3
24 Nov 2025Competitor HK inno.N secures a 2.7x price increase on 11 exit-prevention IV items [S6-rel]Signals a cost-based price-adjustment path for the sector
27 Jan 2026Daihan publishes its 80-year corporate history; Dailypharm profiles a 10-year cumulative OP above KRW 300 bn with average OPM of about 18% [S8]Reputation and positioning
Jan 2026Chairman Lee continues buying; stake 24.63% [S18]Insider support
11 Feb 2026Board approves FY2025 DPS of KRW 1,000 (total ≈KRW 5.9 bn; yield 3.3%) [S16][S15]Fifth consecutive increase; payout about 21%
18 Mar 2026FY2025 results disclosed: revenue KRW 208.6 bn, OP KRW 31.2 bn (-18.1%), NI KRW 27.6 bn; equity KRW 300.2 bn [S27][S5]Earnings inflection
26 Mar 2026Government approves a drug-pricing overhaul cutting generic prices from 53.55% to 45% of the originator price, while strengthening support for exit-prevention drugs [S26]Mixed: Daihan's core is protected; new generics are less valuable
Mar–Apr 2026US–Iran conflict and Hormuz disruption push naphtha prices up about 50%; MFDS asks MOTIE to prioritise naphtha for IV bags [S6][S7]Raw-material and packaging cost shock
1–2 Apr 2026MFDS announces regulatory support for naphtha allocation; the MFDS Minister visits IV makers [S7-rel]Supply-security support
13–14 Apr 2026MOHW, HIRA and NHIS hold working-level talks; a temporary IV price-linkage mechanism is floated but not decided [S7]Potential pricing relief
17 Apr 2026FY2025 dividend paid [S15]–
28 Apr 2026Dailypharm reports Daihan's FY2025 IV revenue down 9% to KRW 142.7 bn; HK inno.N up 16% to KRW 141.7 bn, so the gap shrank to about KRW 1 bn [S6]Competitive share loss
May 2026Q1 2026: revenue about KRW 52.7 bn (+5.6%), OP about KRW 7.9 bn (-14%) (derived) [S2]Volume recovery, margin pressure
16 May 2026MOHW pre-announces a 10% rise in exit-prevention price thresholds (injectables KRW 5,257 → 5,783), +3% for stable suppliers, and +1% each for 7 criteria [S25]Structural pricing support for Daihan's core
5 Jun 2026Chairman's stake reaches 24.75% after buying 4,387 shares [S17]Insider support
~Jul 2026MOHW policy for rapid price increases on supply-unstable products where profitability is the cause [S-kpanews 537815]Pricing support
31 Jul 2026Daihan named one of 18 "Supply-Stability Leading Companies" [S10]50% generic price-calculation premium; recognition of exit-prevention focus
Aug 2026Generic pricing at 45% takes effect [S10-rel]Sector headwind; Daihan's exposure is limited
6 Aug 2026Abbreviated large-shareholding report filed [S5]Filer not identified
14 Aug 2026H1 2026 report: revenue about KRW 109.3 bn (+7.8%), OP about KRW 15.9 bn (-6%) (derived) [S5][S2]Recovery in volumes; margins compressed
20 Aug 2026Related-party stake 39.96%; chairman 24.96% [S1]–
26 Aug 2026KIR initiation: FY2026F revenue KRW 220.0 bn, OP KRW 29.5 bn, NI KRW 25.0 bn; PER 6.4x, PBR 0.5x; net cash KRW 121.4 bn [S1]Third-party valuation anchor
31 Aug, 30 Sep, 8 Oct 2026Further insider ownership-change reports [S5]Continued insider activity

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

5 charts
Income Statement: Revenue & Gross Profit: Revenue rose from KRW 205.1 Bn in Mar-2025 to KRW 216.6 Bn in Jun-2026.
Daihan Pharmaceutical Co., Ltd. — Income Statement: Revenue & Gross Profit
Series (KRW Bn)Mar-2025FY2025Jun-2026
Revenue205.1208.6216.6
Cost of sales135.6143.8152.4
Gross profit69.264.864.1

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Sources

  1. S1Korea IR Council (한국IR협의회), *대한약품 (023910) 수액제 오디세이*, company report, 26 Aug 2026 — (accessed through search-result excerpts) (stock.pstatic.net)
  2. S2ValueLine/DataHero, Daihan income statement (DART stand-alone, TTM series incl. 26.2Q) (valueline.co.kr)
  3. S2-summaryValueLine company summary (valueline.co.kr)
  4. S3ValueLine balance sheet (valueline.co.kr)
  5. S4ValueLine cash-flow statement (valueline.co.kr)
  6. S5Butler, Daihan company dashboard (annual results, mix, filings list, consensus) (butler.works)
  7. S6Dailypharm, "의료대란 변수에 수액제 시장 요동…중동전쟁 변수 촉각", 28 Apr 2026 (dailypharm.com)
  8. S6-relDailypharm, "이노엔 수액제 내달 2.7배 약가인상...퇴방약 11품목 조정", 24 Nov 2025 (related-article listing in S6)
  9. S7Dailypharm, "나프타 가격 인상에 수액제 직격탄...약가연동제 필요성 대두", 14 Apr 2026 (dailypharm.com)
  10. S8Dailypharm, "'3000억·18%·무차입'…대한약품이 쌓은 80년의 숫자들", 27 Jan 2026 (dailypharm.com)
  11. S9Dailypharm, "지분 승계·비전 제시...이승영 대한약품 대표의 과제", 26 Jun 2025 (dailypharm.com)
  12. S10Dailypharm, "JW중외 등 18개사, 약가우대 '수급안정 선도기업' 지정", 31 Jul 2026 — (and the related 1 Aug 2026 article: dailypharm.com · dailypharm.com
  13. S11Daihan Pharm. company website: business page · history · product gallery · product catalogue · home
  14. S12LS Securities, Daihan company report, 2 Jul 2025 (file.alphasquare.co.kr)
  15. S13eBest Investment & Securities, 1Q24 Review, 17 May 2024 (alphasquare-hosted PDF); also eBest 2Q19 / 2Q20 / 3Q21 / 2Q22 / 1Q23 reviews (alphasquare)
  16. S14JobKorea company profile (employees 768 at 30 Jun 2026; FY2025 product mix; financials) (jobkorea.co.kr)
  17. S15ETF Shopping, Daihan dividend history · etfshopping.com
  18. S16Dailypharm, FY2025 pharma dividends analysis, 20 Mar 2026 (m.dailypharm.com)
  19. S17Digital Today, "이윤우 회장, 대한약품 주식 4387주 추가 매수", Jun 2026 (digitaltoday.co.kr)
  20. S18Medipana News, "이윤우 대한약품 회장 '책임 경영', 올해도 지속 실천", Jan 2026 (medipana.com)
  21. S19Dailypharm, "주가 부진 대한약품…3대주주 38억원 규모 줄매도", 5 Dec 2023 (m.dailypharm.com)
  22. S20Dailypharm, "대한약품 '쓰리챔버 영양수액' 론칭 지체...무슨 이유?", 27 Nov 2023 — (related article: "3세 체제 대한약품, 무차입 경영 돌입 '167억→0원'") (dailypharm.com)
  23. S21Hankyung Business magazine, TPN market article, Feb 2024 (magazine.hankyung.com)
  24. S22Butler, JW Life Science dashboard (butler.works)
  25. S23Dealsite, HK inno.N FY2025 results, 10 Feb 2026 (dealsite.co.kr)
  26. S24Dealsite, JW Pharmaceutical FY2025 results, 2 Feb 2026 (dealsite.co.kr)
  27. S25News1 via Nate, "정부, 필수의약품 지원 강화…퇴장방지의약품 약가 기준 10% 인상", 16 May 2026 (m.news.nate.com)
  28. S26Shin & Kim (법무법인 세종) newsletter, NHI pricing overhaul analysis, 9 Apr 2026 (shinkim.com)
  29. S27HitNews, FY2025 earnings disclosure summary, 18 Mar 2026 (hitnews.co.kr)
  30. S28Dailypharm, "대한약품 첫 종합영양수액제 도전, 연착륙 전략 있나", 19 Jan 2022 (m.dailypharm.com)
  31. S29eBest Investment & Securities, valuation report, 2 Dec 2021 (alphasquare-hosted PDF)
  32. S30Dailypharm, "대한약품, 이승영 단독대표 가동…3세 경영 본격화", 3 Apr 2023 (m.dailypharm.com)
  33. S30-2Dailypharm, "대한약품 최대주주 잇단 장내매수...주가하락 의식했나", 27 Apr 2023 (m.dailypharm.com)
  34. S31HealthKorea News, "[제약회사 경영 리더십-대한약품공업]…", 2019 (hkn24.com)
  35. S32Dailypharm, "대한약품 후계자 지분매입 속도...올해 23차례 주식매수", 11 Jun 2019 (m.dailypharm.com)
  36. S33StockHub, Daihan quote page (52-week range) (stockhub.kr)
  37. S34Dailypharm, "대한약품, 영업익 3년 연속 줄고 1년 주가 35% 하락" (FY2021 data: 98% domestic, R&D 0.47%) (m.dailypharm.com)
  38. S35Jasoseol company insight (aggregator) (jasoseol.com)
  39. S36Dailypharm, "'고점인가' 대한약품 2대주주 석달간 30억 처분", 5 Sep 2023 (m.dailypharm.com)
  40. S37Medical Times, "의수협 회장에 이윤우 대한약품 대표 취임", 27 Feb 2009 (medicaltimes.com)
  41. S39Dailypharm, "대한약품 후계자의 숙제 '낮은 지분+넥스트 수액 찾기'", 6 Nov 2020 (m.dailypharm.com)
  42. S-newsthevoiceNews The Voice Healthcare, Daihan profile (2019 board roster; no affiliates) (newsthevoice.com)
  43. S-newstomatoNewsTomato, succession report, 6 Sep 2023 (newstomato.com)
  44. [S-MOHW 2025]: MOHW, 2025 actual-transaction price adjustment guideline (exit-prevention exclusion) (mohw.go.kr)
  45. [S-kpanews 537815]: KPA News, exit-prevention drug list July 2026 (629 products / 374 ingredients) (kpanews.co.kr)
  46. [S-wikidocs JWLS]: JW Life Science Q3 2025 filing analysis (TPN share 54.6%; R&D 2.5%) (wikidocs.net)
  47. S-roicroic.ai Daihan profile (roic.ai)
  48. [S-sidae 2025]: Sidae Ilbo, treasury-share cancellation legislation, Jul 2025 (sidae.com)
  49. [S-dailypharm 38752]: Dailypharm, 29 Jun 2022 (dailypharm.com)
  50. [S-dailypharm 341047]: Dailypharm, 1 Aug 2026 (dailypharm.com)
  51. [S-dailypharm 2024-01]: Dailypharm, 5 Jan 2024 (m.dailypharm.com)
  52. [S-dailypharm 2023-12]: Dailypharm, 28 Dec 2023 (m.dailypharm.com)

[S-Daishin 2024]: Daishin Securities initiation, 9 Jan 2024 (alphasquare-hosted PDF)

[S-eBest 2022]: eBest Investment & Securities, 2Q22 Review, 17 Aug 2022 (alphasquare-hosted PDF)

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.